{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T10:59:53Z","timestamp":1762340393653},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2011,1,20]],"date-time":"2011-01-20T00:00:00Z","timestamp":1295481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The impact of bevacizumab on functional recovery and histology of the liver was evaluated in patients undergoing hepatic resection for colorectal liver metastases (CLM) following bevacizumab treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Consecutive patients who had resection of CLM between July 2005 and July 2009 following preoperative chemotherapy were identified retrospectively from a prospectively collected database. Patients who had received bevacizumab before the last chemotherapy line were excluded. Postoperative liver function and histology were compared between patients with and without bevacizumab treatment. Recorded parameters included serum prothrombin time, total bilirubin concentration, and levels of aspartate and alanine aminotransferase and \u03b3-glutamyltransferase.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 208 patients identified, 67 had received last-line bevacizumab, 44 were excluded and 97 had not received bevacizumab. Most patients in the bevacizumab group (66 per cent) received a single line of chemotherapy. Bevacizumab was most often combined with 5-flurouracil\/leucovorin and irinotecan (68 per cent). The median number of bevacizumab cycles was 8\u00b76 (range 1\u201334). Bevacizumab administration was stopped a median of 8 (range 3\u201319) weeks before surgery. There were no deaths. Postoperative morbidity occurred in 43 and 36 per cent of patients in the bevacizumab and no-bevacizumab groups respectively (P = 0\u00b7353). The mean(s.d.) degree of tumour necrosis was significantly higher in the bevacizumab group (55(27) versus 32(29) per cent; P = 0\u00b7001). Complete pathological response rates were comparable (3 versus 8 per cent; P = 0\u00b7307). Postoperative changes in functional parameters and objective signs of hepatic toxicity were similar in both groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Preoperative administration of bevacizumab does not seem to affect functional recovery of the liver after resection of CLM. Tumour necrosis is increased following bevacizumab treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/bjs.7368","type":"journal-article","created":{"date-parts":[[2010,12,15]],"date-time":"2010-12-15T17:49:34Z","timestamp":1292435374000},"page":"399-407","source":"Crossref","is-referenced-by-count":47,"title":["Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases"],"prefix":"10.1093","volume":"98","author":[{"given":"D A","family":"Wicherts","sequence":"first","affiliation":[{"name":"Centre H\u00e9pato-Biliaire, Assistance Publique-H\u00f4pitaux de Paris (AP-HP) H\u00f4pital Paul Brousse ,","place":["France"]},{"name":"Department of Surgery, University Medical Centre Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R J","family":"de Haas","sequence":"additional","affiliation":[{"name":"Centre H\u00e9pato-Biliaire, Assistance Publique-H\u00f4pitaux de Paris (AP-HP) H\u00f4pital Paul Brousse ,","place":["France"]},{"name":"Department of Surgery, University Medical Centre Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Sebagh","sequence":"additional","affiliation":[{"name":"Department of Pathology, Assistance Publique-H\u00f4pitaux de Paris (AP-HP) H\u00f4pital Paul Brousse ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Saenz Corrales","sequence":"additional","affiliation":[{"name":"Centre H\u00e9pato-Biliaire, Assistance Publique-H\u00f4pitaux de Paris (AP-HP) H\u00f4pital Paul Brousse ,","place":["France"]},{"name":"Department of Surgical Oncology, Calderon Guardia Hospital , San Jos\u00e9, Costa Rica,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D L","family":"Gorden","sequence":"additional","affiliation":[{"name":"Centre H\u00e9pato-Biliaire, Assistance Publique-H\u00f4pitaux de Paris (AP-HP) H\u00f4pital Paul Brousse ,","place":["France"]},{"name":"Departments of Surgery and Cancer Biology, Vanderbilt University School of Medicine , Nashville, Tennessee,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"L\u00e9vi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Assistance Publique-H\u00f4pitaux de Paris (AP-HP) H\u00f4pital Paul Brousse ,","place":["France"]},{"name":"INSERM, Laboratoire \u2018Rythmes biologiques et cancers\u2019 Unit\u00e9 776 ,","place":["France"]},{"name":"Universit\u00e9 Paris-Sud, Unit\u00e9 Mixte de Recherche en Sant\u00e9 ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Paule","sequence":"additional","affiliation":[{"name":"Centre H\u00e9pato-Biliaire, Assistance Publique-H\u00f4pitaux de Paris (AP-HP) H\u00f4pital Paul Brousse ,","place":["France"]},{"name":"Department of Medical Oncology, Assistance Publique-H\u00f4pitaux de Paris (AP-HP) H\u00f4pital Paul Brousse ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Azoulay","sequence":"additional","affiliation":[{"name":"Centre H\u00e9pato-Biliaire, Assistance Publique-H\u00f4pitaux de Paris (AP-HP) H\u00f4pital Paul Brousse ,","place":["France"]},{"name":"INSERM Unit\u00e9 1004 , Villejuif,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Castaing","sequence":"additional","affiliation":[{"name":"Centre H\u00e9pato-Biliaire, Assistance Publique-H\u00f4pitaux de Paris (AP-HP) H\u00f4pital Paul Brousse ,","place":["France"]},{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), Unit\u00e9 785 ,","place":["France"]},{"name":"Universit\u00e9 Paris-Sud, Unit\u00e9 Mixte de Recherche en Sant\u00e9 ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Adam","sequence":"additional","affiliation":[{"name":"Centre H\u00e9pato-Biliaire, Assistance Publique-H\u00f4pitaux de Paris (AP-HP) H\u00f4pital Paul Brousse ,","place":["France"]},{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), Unit\u00e9 785 ,","place":["France"]},{"name":"Universit\u00e9 Paris-Sud, Unit\u00e9 Mixte de Recherche en Sant\u00e9 ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,3,1]]},"reference":[{"key":"2024092904552661500_bib1","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"2024092904552661500_bib2","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1200\/JCO.2005.00.232","article-title":"Combined analysis of efficacy: the addition of bevacizumab to fluorouracil\/leucovorin improves survival for patients with metastatic colorectal cancer","volume":"23","author":"Kabbinavar","year":"2005","journal-title":"J Clin Oncol"},{"key":"2024092904552661500_bib3","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J Clin Oncol"},{"key":"2024092904552661500_bib4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","article-title":"Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases","volume":"230","author":"Fong","year":"1999","journal-title":"Ann Surg"},{"key":"2024092904552661500_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/SLA.0b013e31815aa2c2","article-title":"Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients","volume":"247","author":"Rees","year":"2008","journal-title":"Ann Surg"},{"key":"2024092904552661500_bib6","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/annonc\/mdi246","article-title":"Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates","volume":"16","author":"Folprecht","year":"2005","journal-title":"Ann Oncol"},{"key":"2024092904552661500_bib7","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1023\/A:1008347829017","article-title":"Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery","volume":"10","author":"Giacchetti","year":"1999","journal-title":"Ann Oncol"},{"key":"2024092904552661500_bib8","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/01.sla.0000141198.92114.f6","article-title":"Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival","volume":"240","author":"Adam","year":"2004","journal-title":"Ann Surg"},{"key":"2024092904552661500_bib9","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0140-6736(08)60455-9","article-title":"Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial","volume":"371","author":"Nordlinger","year":"2008","journal-title":"Lancet"},{"key":"2024092904552661500_bib10","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1245\/s10434-006-9074-0","article-title":"Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case\u2013control study","volume":"14","author":"D'Angelica","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"2024092904552661500_bib11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jamcollsurg.2007.06.290","article-title":"Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases","volume":"206","author":"Reddy","year":"2008","journal-title":"J Am Coll Surg"},{"key":"2024092904552661500_bib12","doi-asserted-by":"crossref","first-page":"5254","DOI":"10.1200\/JCO.2008.17.7857","article-title":"Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases","volume":"26","author":"Kesmodel","year":"2008","journal-title":"J Clin Oncol"},{"key":"2024092904552661500_bib13","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1200\/JCO.2005.23.754","article-title":"Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab","volume":"23","author":"Ellis","year":"2005","journal-title":"J Clin Oncol"},{"key":"2024092904552661500_bib14","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1245\/s10434-009-0447-z","article-title":"Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab","volume":"16","author":"Aussilhou","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"2024092904552661500_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2024092904552661500_bib16","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.ejso.2007.09.017","article-title":"Bringing unresectable liver disease to resection with curative intent","volume":"33","author":"Wicherts","year":"2007","journal-title":"Eur J Surg Oncol"},{"key":"2024092904552661500_bib17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"2024092904552661500_bib18","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/01.sla.0000189131.90876.9e","article-title":"The \u201850\u201350 criteria\u2019 on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy","volume":"242","author":"Balzan","year":"2005","journal-title":"Ann Surg"},{"key":"2024092904552661500_bib19","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1245\/s10434-008-0035-7","article-title":"Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases","volume":"15","author":"Zorzi","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"2024092904552661500_bib20","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.2007.13.7679","article-title":"Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer","volume":"26","author":"Gruenberger","year":"2008","journal-title":"J Clin Oncol"},{"key":"2024092904552661500_bib21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/SLA.0b013e3181ad85b5","article-title":"Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity","volume":"250","author":"Stockmann","year":"2009","journal-title":"Ann Surg"},{"key":"2024092904552661500_bib22","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1200\/JCO.2006.05.8156","article-title":"Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases","volume":"24","author":"Aloia","year":"2006","journal-title":"J Clin Oncol"},{"key":"2024092904552661500_bib23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/SLA.0b013e31815774de","article-title":"Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy","volume":"247","author":"Nakano","year":"2008","journal-title":"Ann Surg"},{"key":"2024092904552661500_bib24","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1002\/cncr.23099","article-title":"Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases","volume":"110","author":"Ribero","year":"2007","journal-title":"Cancer"},{"key":"2024092904552661500_bib25","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ejso.2008.12.013","article-title":"Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX\/FOLFOX therapy of colorectal cancer liver metastases","volume":"35","author":"Klinger","year":"2009","journal-title":"Eur J Surg Oncol"},{"key":"2024092904552661500_bib26","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1365-2559.2010.03511.x","article-title":"Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis","volume":"56","author":"Rubbia-Brandt","year":"2010","journal-title":"Histopathology"},{"key":"2024092904552661500_bib27","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2007.13.7471","article-title":"Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality?","volume":"26","author":"Adam","year":"2008","journal-title":"J Clin Oncol"},{"key":"2024092904552661500_bib28","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1200\/JCO.2008.17.5299","article-title":"Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases","volume":"26","author":"Blazer","year":"2008","journal-title":"J Clin Oncol"},{"volume-title":"2007 Gastrointestinal Cancer Symposium","author":"Kretzschmar","key":"2024092904552661500_bib29"},{"key":"2024092904552661500_bib30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jso.20301","article-title":"Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab","volume":"91","author":"Scappaticci","year":"2005","journal-title":"J Surg Oncol"}],"container-title":["Journal of British Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbjs.7368","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/98\/3\/399\/59424775\/bjs7368.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/98\/3\/399\/59424775\/bjs7368.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T04:55:41Z","timestamp":1727585741000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/98\/3\/399\/6148579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,20]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2011,3,1]]},"published-print":{"date-parts":[[2011,1,20]]}},"URL":"https:\/\/doi.org\/10.1002\/bjs.7368","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"type":"print","value":"0007-1323"},{"type":"electronic","value":"1365-2168"}],"subject":[],"published-other":{"date-parts":[[2011,3]]},"published":{"date-parts":[[2011,1,20]]}}}